



Five-Year Mortality for Adults Entering Human Immunodeficiency Virus Care Under Universal Early Treatment Compared With the General US Population

Jessie K. Edwards,¹ Stephen R. Cole,¹ Tiffany L. Breger,² Lindsey M. Filiatreau,¹ Lauren Zalla,¹ Grace E. Mulholland,¹ Michael A. Horberg,³ Michael J. Silverberg,⁴ M. John Gill,⁵ Peter F. Rebeiro,⁶ Jennifer E. Thorne,⁷ Parastu Kasaie,⁸ Vincent C. Marconi,⁹ Timothy R. Sterling,¹⁰ Keri N. Althoff,⁸ Richard D. Moore,¹¹ and Joseph J. Eron²

¹Department of Epidemiology, University of North Carolina at Chapel Hill, North Carolina, USA; ²School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; ³Kaiser Permanent Mid-Atlantic Permanente Research Institute, Rockville, Maryland, USA; ⁴Kaiser Permanente Northern California, Oakland, California, USA; ⁵Department of Medicine, University of Calgary, Calgary, Alberta, Canada; ⁶Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA; ⁷School of Medicine, Johns Hopkins University, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA; ⁸Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA; ⁹School of Medicine, and Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; ¹⁰Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA; and ¹¹School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA

Background. Mortality among adults with human immunodeficiency virus (HIV) remains elevated over those in the US general population, even in the years after entry into HIV care. We explore whether the elevation in 5-year mortality would have persisted if all adults with HIV had initiated antiretroviral therapy within 3 months of entering care.

Methods. Among 82 766 adults entering HIV care at North American AIDS Cohort Collaboration clinical sites in the United States, we computed mortality over 5 years since entry into HIV care under observed treatment patterns. We then used inverse probability weights to estimate mortality under universal early treatment. To compare mortality with those for similar individuals in the general population, we used National Center for Health Statistics data to construct a cohort representing the subset of the US population matched to study participants on key characteristics.

Results. For the entire study period (1999–2017), the 5-year mortality among adults with HIV was 7.9% (95% confidence interval [CI]: 7.6%–8.2%) higher than expected based on the US general population. Under universal early treatment, the elevation in mortality for people with HIV would have been 7.2% (95% CI: 5.8%–8.6%). In the most recent calendar period examined (2011–2017), the elevation in mortality for people with HIV was 2.6% (95% CI: 2.0%–3.3%) under observed treatment patterns and 2.1% (0.0%–4.2%) under universal early treatment.

Conclusions. Expanding early treatment may modestly reduce, but not eliminate, the elevation in mortality for people with HIV.

Keywords. HIV; antiretroviral therapy; mortality; cohort studies.

While the survival outlook for someone newly diagnosed with human immunodeficiency virus (HIV) was dismal in the 1980s and early 1990s, new classes of antiretroviral drugs, improved medical care, and updated public health guidelines have dramatically improved survival for people with HIV. Decades of randomized trials and observational studies have documented significant reductions in mortality after initiation of new treatments and rollout of new treatment guidelines [1–3]. However, mortality rates among people with HIV remain elevated above those in the general US population, even after entry into HIV care [4].

The underlying factors driving this lingering elevation in mortality are unknown and likely multifactorial. Even in the “test-and-treat” era, delays in presentation to care [5], delays in antiretroviral treatment (ART) initiation [6], and losses to clinical follow-up persist [7–10]. Moreover, existing medications are imperfect and may have uncertain safety with long-term use [11, 12]. In addition, there are shared structural and behavioral factors that increase the risk of both HIV acquisition and mortality [13], and people with HIV may also be living with other chronic conditions that are associated with increased mortality rates [14–17].

In the current study, we examined whether the remaining elevation in 5-year mortality among adults with HIV, compared with the US population, would have persisted under modern universal early treatment initiation. Specifically, we compared 5-year mortality among 82 766 adults entering HIV care at a North American AIDS Cohort Collaboration (NA-ACCORD) clinical site in the United States under a hypothetical intervention on treatment timing with the expected 5-year mortality

Received 10 December 2021; published online 4 January 2022.

Correspondence: Jessie K. Edwards, Department of Epidemiology, University of North Carolina at Chapel Hill, 135 Dauer Dr, 2101 McGavran-Greenberg Hall, CB 7435, Chapel Hill, NC 27510 (jessiedwards@unc.edu).

Clinical Infectious Diseases® 2022;75(5):867–74

© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. <https://doi.org/10.1093/cid/ciab1030>

among these individuals if they had the same covariate-specific mortality risk as the US population, with the expected risk computed using aggregate data from the National Center for Health Statistics (NCHS). Quantifying the elevation in mortality that remains after universal early treatment can inform efforts to improve care for people with HIV.

METHODS

Data Sources

US Population and Mortality Data

We obtained data on the 47 812 945 deaths occurring in the United States from 1999 to 2017, using the NCHS detailed mortality files. We aggregated the number of deaths for each year by age (year), sex (male/female), race (white, black, American Indian, or Asian/Pacific Islander), ethnicity (Hispanic/non-Hispanic), and county of residence. We merged the mortality data with census data provided by the NCHS describing the estimated population size in each of the strata defined above for all US counties over the relevant time period. These merged data, containing both the number of deaths and population size by year, age, sex, race, ethnicity, and county of residence, composed our “US population and mortality” data set.

HIV Cohort Data

Data on adults with HIV in the United States were obtained from the NA-ACCORD [18], which includes 29 contributing single and multisite clinical and interval epidemiologic cohorts of HIV-seropositive participants that encompass many longitudinal HIV/AIDS cohort studies in the United States and Canada and has demonstrated that the demographic characteristics of its US participants are similar to those of individuals receiving new HIV diagnoses in the United States, as captured by the US Centers for Disease Control and Prevention’s HIV surveillance system [19, 20].

Participants were enrolled in NA-ACCORD contributing cohorts if written informed consent or a waiver of consent was obtained; research activities involving human subjects have been approved by each cohort’s local institutional review board and the Johns Hopkins School of Medicine. Data are collected according to individual cohort protocol, harmonized by the NA-ACCORD Data Management Core (Washington University, Seattle), and assembled into analysis data files by the NA-ACCORD Epidemiology/Biostatistics Core (Johns Hopkins University, Baltimore, Maryland). NA-ACCORD enrollment criteria include successful linkage to care, defined as a ≥ 2 HIV care visits within 12 months. Participants are observed to disengage and reengage in care after linkage. For this analysis, we included data from US cohorts that contribute data collected through routine clinical HIV care. Interval cohorts were excluded so that results characterized patients actively in care. Data-driven cohort open and close dates for each participating cohort, established by NA-ACCORD after reviewing core data

(eg, dates of death, biomarker measurements, and ART prescriptions), are shown in [Supplementary Figure 1](#) [21].

Covariates for the current analysis included age at entry into NA-ACCORD, birth sex, race/ethnicity, zip code, CD4 cell count at NA-ACCORD enrollment, and HIV transmission risk factors. We harmonized covariate data between NA-ACCORD and NCHS data by collapsing race and ethnicity into a single measure, including the categories non-Hispanic white, non-Hispanic black, non-Hispanic Asian, non-Hispanic American Indian/Alaska native, and Hispanic.

In NA-ACCORD, place of residence was provided using 3- or 5-digit zip codes rather than counties. To cohere with the population and mortality data for the general population, we mapped 5-digit zip codes to counties using zip code to county crosswalk tables provided by the US Department of Housing and Urban Development [22]. When only 3-digit zip codes were provided, we mapped the 3-digit zip code to a list of possible counties using the same crosswalk tables. We excluded 1 cohort that did not provide data on zip code of residence.

Mortality data, including dates of death, for participants in NA-ACCORD were obtained through regular queries to the Social Security Death Index, the National Death Index, or state vital statistics registries. Dates of death were imputed for decedents with missing information on day or month of death (on the 15th day or 6th month of the year, respectively). Dates of first ART (“treatment”) and clinic visits were abstracted from clinical records.

For our analysis, we identified 90 639 patients aged ≥ 18 years of age who newly enrolled in HIV care at NA-ACCORD clinical cohort sites in the United States during or after 1999. We identified patients who were newly enrolled in care as those who did not have a recorded date of treatment initiation or AIDS diagnosis before cohort enrollment date or a suppressed viral load (<75 copies/mL) measured between 30 days before and 7 days after date of entry into care. We excluded 3 intersex patients who could not be matched to the US population data, 7833 patients (8.6%) with missing data on covariates, including race/ethnicity ($n = 4687$) and/or zip code at study entry ($n = 3376$), and 34 patients with unknown years of death, for a final analytic sample of 82 766 patients ([Supplementary Figure 2](#)). We assessed the sensitivity of our results to these exclusions by comparing overall mortality risks before and after excluding those with missing covariate data.

Statistical Methods

To estimate 5-year mortality risks, patients were observed from NA-ACCORD enrollment (occurring after the cohort open date and 1 January 1999), until whichever of the following occurred first: death, loss to follow-up, administrative censoring 5 years after study entry, the cohort close date, or 31 December 2017. Patients were considered lost to follow-up on the date when they had had a 12-month gap between clinic visits at an

NA-ACCORD site [23]. In supplemental analyses, we censored participants on the date when they had an 18-month gap in care to assess the robustness of findings to our definition of loss to follow-up.

We compared 5-year mortality between (1) adults entering HIV care under their observed treatment patterns; (2) adults entering HIV care had they, possibly contrary to fact, started treatment within 3 months of entry into care (universal early treatment); and (3) this set of patients had they been subject to the same age-, sex-, race/ethnicity-, and county-specific mortality rates as the US population (expected mortality).

We estimated the 5-year mortality (ie, the cumulative risk [24] of death 5 years after entry into care) among those entering HIV care under observed treatment patterns using the complement of the Kaplan-Meier estimator of the survival function [25]. We applied stabilized inverse probability of censoring weights to account for informative censoring [26]. We included covariates thought to be associated with censoring and mortality including age, sex, race/ethnicity, site, self-reported HIV transmission risk factors, and time-varying CD4 cell count and log₁₀ HIV viral load in the weights. Age, CD4 cell count, and HIV viral load were included as continuous variables, modeled using restricted quadratic splines [27].

To estimate mortality among people entering care for HIV had they experienced “early” treatment, we additionally censored patients at 3 months if they had not yet started treatment. To compute mortality under this treatment plan, we applied both the standard inverse probability of censoring weights to account for informative loss to follow-up and a second weight to account for preferential early treatment of certain types of patients. The purpose of this approach was to weight participants remaining in the data set at each time point to have the same distribution of baseline and time-varying covariates as those in the target population (ie, all adults entering care for HIV at a US clinical NA-ACCORD site, irrespective of ART timing). We included the covariates listed above in the treatment weights, because these variables were thought to be associated with both treatment timing and mortality. We estimated 5-year mortality under universal early treatment using the complement of the weighted Kaplan-Meier estimator, and we computed 95% confidence intervals (CIs) around weighted mortality estimates using robust standard errors. Details are provided in Appendix 1.

We estimated expected mortality among eligible patients (had they experienced the same age-, sex-, race/ethnicity-, and county-specific mortality as the general US population) using the approach previously described by Edwards et al [4]. Briefly, we created a population-based synthetic cohort [28] of people in the United States of the same age in the same year, matched to each eligible participant starting care at an NA-ACCORD site for sex, race/ethnicity, and county of residence, using the NCHS data. We computed the mortality in each synthetic cohort, using the Kaplan-Meier estimator, and averaged mortality

risk functions across all synthetic cohorts to estimate the overall expected mortality risk function among eligible people in NA-ACCORD (Appendix 2).

We stratified the estimates of 5-year mortality risks by calendar period of entry into HIV care: 1999–2004, 2005–2010, and 2011–2017. We also estimated risk differences overall and by calendar period, comparing 5-year mortality risks among those entering care for HIV (both under the treatment patterns observed and universal early treatment) with those in the US population. Standard errors and 95% CIs for the risk differences were obtained using the delta method [29].

RESULTS

Overall, 82 766 eligible adults entered care for HIV at a participating NA-ACCORD clinical site between 1999 and 2017. Nearly half (46%) were non-Hispanic black, 35% were non-Hispanic white, and 16% were Hispanic (Table 1). The majority of patients were between the ages of 35 and 54 year at entry into care (57%), and most patients were male (84%).

Where measured, the median CD4 cell count at study entry increased from 284/ μ L (interquartile range, 105–479/ μ L) among patients entering NA-ACCORD between 1999 and 2004 to 366/ μ L (175–558/ μ L) among those entering between 2011 and 2017. The probability of starting treatment in the first 3 months after entering HIV care rose over time from 41% among those entering care between 1999 and 2004 to 71% among those entering care between 2011 and 2017 (Figure 1). Treatment regimens also shifted over time, with nearly all treated patients starting protease inhibitors or nonnucleoside reverse-transcriptase inhibitors in the first calendar period and nearly 40% starting an integrase inhibitor-containing regimen by the most recent calendar period (Supplementary Figure 3).

Among adults entering care for HIV, the 5-year mortality risk while in care was 10.9% under the observed patterns of treatment and 10.1% under universal early treatment. In the matched US population, the 5-year mortality risk was 2.9% (Table 2). Over calendar time, 5-year mortality risks among adults entering care for HIV dropped dramatically, both under observed treatment patterns and under universal early treatment, while 5-year mortality risks in the matched US population declined only slightly (Supplementary Figure 4).

The overall mortality risk difference (quantifying the gap in 5-year mortality risks between adults in care for HIV and the matched US population) was smaller under universal early treatment (difference, 7.2% [95% CI: 5.8%–8.6%]) than under the observed treatment patterns (7.9% [7.6%–8.2%]) (Figure 2). Mortality risk differences between adults in care for HIV and the matched US population declined over time, such that, in the most recent calendar period from 2011 to 2017, adults entering care for HIV were only 2.6% (95% CI: 2.0%–3.3%) more likely to die within the first 5 years of HIV

Table 1. Characteristics of 82 766 Eligible Patients Entering Care for Human Immunodeficiency Virus Between 1999 and 2017, Stratified by Calendar Period at Entry into Care

Characteristic	Overall	Patients, No. (%)		
		Entered Care in 1999–2004	Entered Care in 2005–2010	Entered Care in 2011–2017
Race/ethnicity				
NH white	29 084 (35.1)	11 994 (36.8)	9099 (33.6)	7991 (34.6)
NH black	38 263 (46.2)	15 133 (46.4)	12 854 (47.4)	10 276 (44.5)
NH American Indian	350 (0.4)	131 (0.4)	118 (0.4)	101 (0.4)
NH Asian/Pacific Islander	1463 (1.8)	379 (1.2)	468 (1.7)	616 (2.7)
Hispanic	13 606 (16.4)	4951 (15.2)	4565 (16.8)	4090 (17.7)
Age at study entry				
18–34	23 169 (28.0)	7219 (22.2)	7564 (27.9)	8386 (36.3)
35–54	47 067 (56.9)	21 261 (65.2)	15 221 (56.2)	10 585 (45.9)
≥55	12 530 (15.1)	4108 (12.6)	4319 (15.9)	4103 (17.8)
Sex				
Female	13 448 (16.2)	5412 (16.6)	4674 (17.2)	3362 (14.6)
Male	69 318 (83.8)	27 176 (83.4)	22 430 (82.8)	19 712 (85.4)
US region of residence ^a				
Northeast and mid-Atlantic	29 016 (35.1)	11 018 (33.8)	9458 (34.9)	8540 (37.0)
South	27 909 (33.7)	10 591 (32.5)	9540 (35.2)	7778 (33.7)
Midwest and North Central	5332 (6.4)	2844 (8.7)	1471 (5.4)	1017 (4.4)
West	20 509 (24.8)	8135 (25.0)	6635 (24.5)	5739 (24.9)
CD4 cell count at entry into NA-ACCORD, cells/ μ L ^b				
≥750	4483 (5.4)	1396 (4.3)	1463 (5.4)	1624 (7.0)
500–749	9250 (11.2)	2941 (9.0)	3171 (11.7)	3138 (13.6)
350–499	10 047 (12.1)	3296 (10.1)	3601 (13.3)	315 (13.7)
200–349	11 083 (13.4)	4030 (12.4)	4020 (14.8)	3033 (13.1)
<200	17 552 (21.2)	7139 (21.9)	6242 (23.0)	4171 (18.1)
Missing	30 351 (36.7)	13 786 (42.3)	8607 (31.8)	7958 (34.5)
Self-reported HIV transmission risk category ^c				
MSM	28 782 (34.8)	8573 (26.3)	9599 (35.4)	10 610 (46.0)
IDU	14 746 (17.8)	8279 (25.4)	4218 (15.6)	2249 (9.7)
Other	41 192 (49.8)	16 495 (50.6)	13 909 (51.3)	10 788 (46.8)

Abbreviations: HIV, human immunodeficiency virus; IDU, injection drug use; MSM, men who have sex with men; NA-ACCORD, North American AIDS Cohort Collaboration on Research and Design; NH, non-Hispanic.

^aThe region of residence was categorized by the first digit of the zip code, such that those beginning with 0, 1, or 2 were labeled "Northeast or mid-Atlantic," those beginning with 3 or 7 were labeled "South," those beginning with 4, 5, or 6 were labeled "Midwest and North Central," and those beginning with 8 or 9 were labeled "West."

^bThe baseline CD4 cell count was defined as the last count measured between 30 days before and 14 days after a participant's enrollment date.

^cSelf-reported transmission risk category. These categories were not mutually exclusive (ie, some participants appear in both MSM and IDU rows). The "Other" category includes those self-reporting neither MSM nor IDU risk factors but reporting heterosexual transmission, blood transfusions, laboratory or medical settings, other risk factors, or unknown transmission route.

care than matched individuals in the US population. Under the universal early treatment intervention, the mortality risk difference between those entering HIV care and the matched US population in the most recent period was 2.1% (95% CI: −0.0% to 4.2%). Results were similar when censoring at 18, rather than 12, months without a clinic visit (*Supplementary Table 1*), and overall mortality results were similar when analyses were not restricted to those with complete covariate data (*Supplementary Table 2*).

DISCUSSION

We assessed the extent to which a strategy to provide universal early ART to adults entering HIV care would reduce the elevation in mortality rates observed among adults with HIV,

compared with the US population. We estimated that early treatment appeared to reduce, but not eliminate, this elevation in 5-year mortality over the 5 years after entry into HIV care. In the most recent calendar period examined (2011–2017), we estimated that early treatment reduced the elevation in mortality by about 20%: from a 2.6% 5-year mortality risk difference under observed treatment patterns to a 2.1% difference under universal early treatment.

Existing work has shown that people with HIV have higher mortality risks and shorter life expectancy than the US population [4, 17, 30–32], and that early ART is effective in improving survival [1, 2, 30, 33, 34]. We estimated that universal treatment within the first 3 months of care would result in a modest reduction in 5-year mortality risk. This reduction was likely




Figure 1. Probability of starting antiretroviral (ART) over time since entry into human immunodeficiency virus (HIV) care by calendar period among 82 766 patients entering care at US North American AIDS Cohort Collaboration clinical sites between 1999 and 2017.

modest because many patients in the observed NA-ACCORD data did, in fact, receive HIV treatment soon after entry into care. In addition, over the course of the study, treatment guidelines evolved to recommend earlier treatment and the time from entry into care until treatment initiation declined [5]. Therefore, the number of patients whose treatment patterns would have been altered by this intervention declined over time. We would expect to see a stronger effect in a setting (or subgroup) with longer delays in access to treatment or under an intervention to ensure treatment within a smaller time window (eg, within 24 hours, 72 hours, or 1 week of entering care) [35–37].

The remaining elevation in mortality rate observed under universal early treatment initiation could have several causes. Even highly effective treatments may be imperfect, and with increasing life expectancy among people with HIV, the long-term effects of both HIV and ART are only beginning to be more fully observed [17].

Most importantly, early treatment after entry to HIV care is not the same as early treatment for HIV infection because people entering HIV care may have lived for years with uncontrolled HIV before diagnosis and linkage to care. In the current study, the median CD4 cell count at study entry remained low (366/ μ L; <200/ μ L in nearly 20%) even in the most recent time period, and other studies in NA-ACCORD and elsewhere have noted that CD4 cell count at entry into care and treatment initiation remains below 400/ μ L [5, 38, 39]. With an average CD4 cell count decline of approximately 60 cells/ μ L per year [40], a majority of people entering care at an NA-ACCORD site in our cohort were likely untreated for \geq 5 years before entry. Until this infection-to-treatment gap is closed, mortality risks are unlikely to approach those of people without HIV.

The elevation in 5-year mortality observed among people with HIV may also be due in part to their higher risk of other chronic conditions, including metabolic and mental health disorders, and higher prevalence of smoking and substance abuse [14–16, 41–47]. While many of these factors likely manifested before HIV diagnosis, routine engagement with HIV care may offer opportunities to address these factors by providing a forum for early diagnosis, referrals for care, and connection with appropriate resources.

Our results should be interpreted considering the study's limitations. We matched on measured demographic and

Table 2. Five-Year Mortality Risks, Mortality Risk Differences, and Mortality Risk Ratios in 82 766 Patients Entering Care for Human Immunodeficiency Virus in 1999–2017, Under Observed Treatment Patterns and Presumption of Early Treatment, and in a Matched Subset of the General US Population, Overall and by Calendar Period

Patient Group or Population	5-y Mortality Risk, %	Mortality Risk Difference (95% CI), %	Mortality Risk Ratio (95% CI)
Patients entering HIV care during all periods (1999–2017)			
Under observed treatment patterns	10.9	7.9 (7.6–8.2)	3.68 (3.57–3.79)
Under universal early treatment ^a	10.1	7.2 (5.8–8.6)	3.44 (3.29–3.59)
Matched general US population	2.9	0	1
Patients entering HIV care in 1999–2004			
Under observed treatment patterns	15.1	11.7 (11.1–12.2)	4.43 (4.27–4.54)
Under universal early treatment ^a	14.1	10.7 (8.7–12.6)	4.13 (3.92–4.37)
Matched general US population	3.4	0	1
Patients entering HIV care in 2005–2010			
Under observed treatment patterns	8.7	5.7 (5.3–6.2)	2.94 (2.79–3.09)
Under universal early treatment ^a	8.4	5.4 (3.6–7.3)	2.84 (2.64–3.05)
Matched general US population	2.9	0	1
Patients entering HIV care in 2011–2017			
Under observed treatment patterns	4.9	2.6 (2.0–3.3)	2.12 (1.86–2.42)
Under universal early treatment ^a	4.4	2.1 (−0.0 to 4.2)	1.8 (1.52–2.35)
Matched general US population	2.3	0	1

Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus.

^aTreatment within 3 months of entry into care.




Figure 2. Five-year mortality differences (with 95% confidence intervals [CIs]) comparing mortality risks between the matched US general population and 82 766 patients entering care for human immunodeficiency virus at US North American AIDS Cohort Collaboration clinical sites between 1999 and 2017 under both observed treatment patterns (black) and universal early treatment (blue). Points represent mortality risk differences, and lines, 95% CIs.

geographic factors thought to be associated with both HIV and mortality to account for differences between those with HIV and the general population. However, some factors were unmeasured and therefore not accounted for in this analysis. For example, both NA-ACCORD and NCHS lacked information on socioeconomic status and neighborhood, which are related to both HIV incidence and mortality [13, 48–50]. Other factors may have been measured imperfectly. For example, we matched people entering HIV care to people in the US population based on zip code at entry into care; some of these individuals may have moved during the 5-year follow-up and those with 3-digit zip codes matched to more than 1 county.

Moreover, our estimates of risk under early treatment may have been subject to bias if there were unmeasured covariates that were associated with both treatment timing and mortality. For example, if current injection drug use and housing instability, both unmeasured, were associated with later treatment and higher mortality risks, early treatment may have appeared misleadingly effective. While we included the set of covariates typically used to model the effects of ART [51, 52] and treatment timing [53], these social determinants of health (and others, like education and income) may be responsible in part for both the gap in mortality risks between those with HIV and the US population and between those with HIV with or without early treatment.

HIV clinical care has made immense gains in improving survival for people with HIV, but we estimate that they would continue to have higher 5-year mortality risks than the US population even if started on ART within 3 months of entry into care. Further reducing this remaining elevation in mortality risks will likely require reducing the time from HIV infection to linkage to care [54–57] and may require additional strategies

aimed at treating and preventing other chronic conditions among people receiving HIV care.

Supplementary Data

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Disclaimer. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (NIH).

Financial support. This work was supported by the NIH (grants K01AI125087, K01AI138853, R01AI157758, U01AI069918, F31AI124794, F31DA037788, G12MD007583, K01AI093197, K01AI131895, K23EY013707, K24AI065298, K24AI118591, K24DA000432, KL2TR000421, N01CP01004, N02CP055504, N02CP91027, P30AI027757, P30AI027763, P30AI027767, P30AI036219, P30AI050409, P30AI050410, P30AI094189, P30AI110527, P30MH62246, R01AA016893, R01DA011602, R01DA012568, R01AG053100, R24AI067039, U01AA013566, U01AA020790, U01AI038855, U01AI038858, U01AI068634, U01AI068636, U01AI069432, U01AI069434, U01DA03629, U01DA036935, U10EY008057, U10EY008052, U10EY008067, U01HL146192, U01HL146193, U01HL146194, U01HL146201, U01HL146202, U01HL146203, U01HL146204, U01HL146205, U01HL146208, U01HL146240, U01HL146241, U01HL146242, U01HL146245, U01HL146333, U24AA020794, U54MD007587, UL1RR024131, UL1TR000004, UL1TR000083, Z01CP010214, and Z01CP010176); the Centers for Disease Control and Prevention (contracts CDC-200-2006-18797 and CDC-200-2015-63931); the Agency for Healthcare Research and Quality (contract 90047713); the Health Resources and Services Administration (contract 90051652); the Canadian Institutes of Health Research (grants CBR-86906, CBR-94036, HCP-97105, and TGF-96118); the Ontario Ministry of Health and Long Term Care; and the Government of Alberta, Canada. Additional support was provided by the National Institute of Allergy and Infectious Diseases (including support to T. R. S.), National Cancer Institute, National Heart, Lung, and Blood Institute, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Human Genome Research Institute, National Institute for Mental Health and National Institute on Drug Abuse, National Institute on Aging, National Institute of Dental and Craniofacial Research, National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research, National Institute on Alcohol Abuse and Alcoholism, National Institute on Deafness and Other Communication Disorders, and National Institute of Diabetes and Digestive and Kidney Diseases.

Potential conflicts of interest. L. M. F. reports payment to their institution from ViiV Healthcare to cover the cost of doctoral training (tuition and associated fees) and to support Statistical Horizons workshop attendance. M. J. S. reports a research grant to his institution from Gilead. M. J. G. has been an ad hoc advisor to national HIV advisory boards for Merck, Gilead, and ViiV Healthcare. P. F. R. reports payment from Gilead for participation in a panel in 2020. V. C. M. received research grants from Gilead Sciences and ViiV Healthcare and served as an advisory board member for Eli Lilly and Novartis. T. R. S. reports royalties from UpToDate for textbook chapters on tuberculosis. K. N. A. serves as a consultant to the All of Us Research Program (NIH) and on the scientific advisory board for TrioHealth. J. J. E. reports ad hoc consultancies to Merck, Gilead Sciences, ViiV Healthcare, and Janssen and contracts to his institution for clinical research, for which he receives support from Gilead Sciences, ViiV Healthcare, and Janssen. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Cain LE, Logan R, Robins JM, et al. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. *Ann Intern Med* **2011**; 154:509–15.
2. Edwards JK, Cole SR, Westreich D, et al. Age at entry into care, timing of antiretroviral therapy initiation, and 10-year mortality among HIV-seropositive adults in the United States. *Clin Infect Dis* **2015**; 61:1189–95.
3. Cole SR, Edwards JK, Hall HI, et al. Incident AIDS or death after initiation of human immunodeficiency virus treatment regimens including raltegravir or efavirenz among adults in the United States. *Clin Infect Dis* **2017**; 64:1591–6.
4. Edwards JK, Cole SR, Breger TL, et al. Mortality among persons entering HIV care compared with the general U.S. population. *Ann Intern Med* **2021**; 174:1197–1206.
5. Lee JS, Humes EA, Hogan BC, et al. CD4 count at entry into HIV care and at antiretroviral therapy prescription in the US, 2005–2018. *Clin Infect Dis* **2021**; 73:e2334–e2337.
6. Fatukasi TV, Cole SR, Moore RD, Mathews WC, Edwards JK, Eron JJ. Risk factors for delayed antiretroviral therapy initiation among HIV-seropositive patients. *PLoS One* **2017**; 12:e0180843.
7. Edwards JK, Cole SR, Westreich D, et al. Loss to clinic and five-year mortality among HIV-infected antiretroviral therapy initiators. *PLoS One* **2014**; 9:e102305–e102305.
8. Geng EH, Bwana MB, Muyindike W, et al. Failure to initiate antiretroviral therapy, loss to follow-up and mortality among HIV-infected patients during the pre-ART period in Uganda. *J Acquir Immune Defic Syndr* **2013**; 63:e64–71.
9. Ndiaye B, Ould-Kaci K, Salleron J, et al. Incidence rate and risk factors for loss to follow-up in HIV-infected patients from five French clinical centres in Northern France - January 1997 to December 2006. *Antivir Ther* **2009**; 14:567–75.
10. Zürcher K, Mooser A, Anderegg N, et al. Outcomes of HIV-positive patients lost to follow-up in African treatment programmes. *Trop Med Int Health* **2017**; 22:375–87.
11. Mary-Krause M, Cotte L, Simon A, Partisan M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. *AIDS* **2003**; 17:2479–86.
12. Keiser O, Fellay J, Opravil M, et al. Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. *Antivir Ther* **2007**; 12:1157–64.
13. Nunn A, Yolken A, Cutler B, et al. Geography should not be destiny: focusing HIV/AIDS implementation research and programs on microepidemics in US neighborhoods. *Am J Public Health* **2014**; 104:775–80.
14. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. *Clin Infect Dis* **2011**; 53:1120–6.
15. Lifson AR, Landis HA. Smoking and HIV: prevalence, health risks, and cessation strategies. *Curr HIV/AIDS Rep* **2012**; 9:223–30.
16. Hartzler B, Dombrowski JC, Crane HM, et al. Prevalence and predictors of substance use disorders among HIV care enrollees in the United States. *AIDS Behav* **2017**; 21:1138–48.
17. Marcus JL, Leyden WA, Alexeef SE, et al. Comparison of overall and comorbidity-free life expectancy between insured adults with and without HIV infection, 2000–2016. *JAMA Netw Open* **2020**; 3:e207954–e207954.
18. Gange SJ, Kitahata MM, Saag MS, et al. Cohort profile: the North American AIDS Cohort Research and Design (NA-ACCORD). *Int J Epidemiol* **2007**; 36:294–301.
19. Althoff KN, Buchacz K, Hall HI, et al. U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. *Ann Intern Med* **2012**; 157:325–35.
20. North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Monitoring HIV. Available at: <https://naaccord.org/>. Accessed 2 June 2021.
21. Althoff KN, Wong C, Hogan B, et al. Mind the gap: observation windows to define periods of event ascertainment as a quality control method for longitudinal electronic health record data. *Ann Epidemiol* **2019**; 33:54–63.
22. Office of Policy Development and Research, US Department of Housing and Urban Development. HUD USPS zip code crosswalk files. Available at: https://www.huduser.gov/portal/datasets/usps_crosswalk.html. Accessed 3 June 2020.
23. Lesko CR, Edwards JK, Cole SR, Moore RD, Lau B. When to censor? *Am J Epidemiol* **2018**; 187:623–32.
24. Cole SR, Hudgens MG, Brookhart MA, Westreich D. Risk. *Am J Epidemiol* **2015**; 181:246–50.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc* **1958**; 53:457–81.
26. Howe CJ, Cole SR, Lau B, Napravnik S, Eron JJ. Selection bias due to loss to follow up in cohort studies. *Epidemiology* **2016**; 27:91–7.
27. Howe CJ, Cole SR, Westreich DJ, Greenland S, Napravnik S, Eron JJ. Splines for trend analysis and continuous confounder control. *Epidemiology* **2011**; 22:874–5.
28. Rudolph JE, Cole SR, Edwards JK, Whitsel EA, Serre ML, Richardson DB. Using animations of risk functions to visualize trends in US all-cause and cause-specific mortality, 1968–2016. *Am J Public Health* **2019**; 109:451–3.
29. Oehlert GW. A note on the delta method. *Am Statist* **1992**; 46:27–9.
30. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. *PLoS One* **2013**; 8:e81355–e81355.
31. Marcus JL, Chao CR, Leyden WA, et al. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. *J Acquir Immune Defic Syndr* **2016**; 73:39–46.
32. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. *Lancet* **2008**; 372:293–9.
33. Danel C, Moh R, Gabillard D, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. *N Engl J Med* **2015**; 373:808–22.
34. Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. *N Engl J Med* **2015**; 373:795–807.
35. Coffey S, Bacchetti P, Sachdev D, et al. RAPID antiretroviral therapy: high virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population. *AIDS* **2019**; 33:825–32.
36. Mateo-Urdiales A, Johnson S, Smith R, Nachega JB, Eshun-Wilson I. Rapid initiation of antiretroviral therapy for people living with HIV. *Cochrane Database Syst Rev* **2019**; 6:CD012962.
37. Halperin J, Butler I, Conner K, et al. Linkage and antiretroviral therapy within 72 hours at a federally qualified health center in New Orleans. *AIDS Patient Care STDS* **2018**; 32:39–41.
38. The iDEA and COHERE Cohort Collaborations. Global trends in CD4 cell count at the start of antiretroviral therapy: collaborative study of treatment programs. *Clin Infect Dis* **2018**; 66:893–903.
39. Lesko CR, Cole SR, Zinski A, Poole C, Mugavero MJ. A systematic review and meta-regression of temporal trends in adult CD4⁺ cell count at presentation to HIV care, 1992–2011. *Clin Infect Dis* **2013**; 57:1027–37.
40. Wolbers M, Babiker A, Sabin C, et al. Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy—the CASCADE collaboration: a collaboration of 23 cohort studies. *PLoS Med* **2010**; 7:e1000239.
41. Burkhalter JE, Springer CM, Chhabra R, Ostroff JS, Rapkin BD. Tobacco use and readiness to quit smoking in low-income HIV-infected persons. *Nicotine Tob Res* **2005**; 7:511–22.
42. Burns DN, Hillman D, Neaton JD, et al; Terry Beirn Community Programs for Clinical Research on AIDS. Cigarette smoking, bacterial pneumonia, and other clinical outcomes in HIV-1 infection. *J Acquir Immune Defic Syndr Hum Retrovirol* **1996**; 13:374–83.
43. Crothers K, Goulet JL, Rodriguez-Barradas MC, et al. Impact of cigarette smoking on mortality in HIV-positive and HIV-negative veterans. *AIDS Educ Prev* **2009**; 21:40–53.
44. Deren S, Cortes T, Dickson VV, et al. Substance use among older people living with HIV: challenges for health care providers. *Front Public Health* **2019**; 7:94.
45. Webb MS, Vanable PA, Carey MP, Blair DC. Cigarette smoking among HIV+ men and women: examining health, substance use, and psychosocial correlates across the smoking spectrum. *J Behav Med* **2007**; 30:371–83.
46. Gallant J, Hsue PY, Shreeve S, Meyer N. Comorbidities among US patients with prevalent HIV infection—a trend analysis. *J Infect Dis* **2017**; 216:1525–33.
47. Remien RH, Stirratt MJ, Nguyen N, Robbins RN, Pala AN, Mellins CA. Mental health and HIV/AIDS: the need for an integrated response. *AIDS* **2019**; 33:1411–20.
48. Rubin MS, Colen CG, Link BG. Examination of inequalities in HIV/AIDS mortality in the United States from a fundamental cause perspective. *Am J Public Health* **2010**; 100:1053–9.
49. Maas B, Fairbairn N, Kerr T, Li K, Montaner JSG, Wood E. Neighborhood and HIV infection among IDU: place of residence independently predicts HIV infection among a cohort of injection drug users. *Health Place* **2007**; 13:432–9.
50. Phillips G, Birkett M, Kuhns L, Hatchell T, Garofalo R, Mustanski B. Neighborhood-level associations with HIV infection among young men who have sex with men in Chicago. *Arch Sex Behav* **2015**; 44:1773–86.
51. Cole SR, Hernán MA, Robins JM, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. *Am J Epidemiol* **2003**; 158:687–94.

52. Lesko CR, Cole SR, Hall HI, et al. The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009–11. *Int J Epidemiol* **2016**;45:140–50.
53. Cain LE, Robins JM, Lanoy E, Logan R, Costagliola D, Hernán M. When to start treatment? a systematic approach to the comparison of dynamic regimes using observational data. *Int J Biostat* **2010**; 6:18.
54. Hayes R, Floyd S, Schaap A, et al. A universal testing and treatment intervention to improve HIV control: one-year results from intervention communities in Zambia in the HPTN 071 (PopART) cluster-randomised trial. *PLoS Med* **2017**; 14:e1002292.
55. Shamu S, Slabbert J, Guloba G, et al. Linkage to care of HIV positive clients in a community based HIV counselling and testing programme: a success story of non-governmental organisations in a South African district. *PLoS One* **2019**; 14:e0210826.
56. Stephenson R, Todd K, Kahle E, et al. Project Moxie: results of a feasibility study of a telehealth intervention to increase HIV testing among binary and nonbinary transgender youth. *AIDS Behav* **2020**; 24:1517–30.
57. Wu Z, Zhao Y, Ge X, et al. Simplified HIV testing and treatment in China: analysis of mortality rates before and after a structural intervention. *PLoS Med* **2015**; 12:e1001874.